We use our own and third party cookies in order to improve our performance, and to obtain anonymous statistics about the use of the website. By continuing to browse, you authorize their use. In order to change the preferences and to obtain further information, please refer to our cookies policy.

Areas
Menu
en

Laboratorios LETI and MSD Animal Health start distribution of vaccine against canine Leishmaniosis

26/02/2018

MSD Animal Health and Laboratorios LETI have started to jointly distribute the Leishmaniasis vaccine LetiFend® in France, Italy and Greece. Great Britain expects to start soon. Canine Leishmaniosis is spread by the bite of certain types of Sandflies.

Therefore, the two companies and European veterinarian specialists on Leishmania met in January at the Laboratorios LETI production plant located in the town of Tres Cantos, Madrid, to inform about the benefits and efficacy of the Leishmaniasis vaccine.

Mr. Jaime Grego, president of Laboratorios LETI, remarked during the opening of the meeting, "Today is an important step in our history that began in 1919. In 2016 we obtained the EMA approval of LetiFend®, in 2017 the distribution agreement with MSD Animal Health for France, Italy, Greece and the United Kingdom and today we are laying the scientific foundations for the prevention of canine leishmaniosis globally to control the spread of this disease in humans."

Dr. Hans-Günther Dittrich, regional vice president MSD Animal Health EURAM, stated that "due to our continuously changing market, MSD Animal Health is always looking for collaborations with the best to maintain leadership in the animal health market. The agreement with Laboratorios LETI offers a holistic solution to the terrible disease of Leishmaniosis, reinforcing the protection and care of animal health as well as our commitment to “One Health" in society.

During the meeting, LETI provided the leading European Leishmania veterinarians and representatives of MSD Animal Health of France, Italy, Greece and Great Britain with scientific data of the vaccine, the manufacturing technology background as well as clinical and scientific LetiFend® studies. After that the participants were taken on a tour through the Laboratorios LETI facilities where they could see for themselves how the Laboratorios LETI immunotherapies are produced with the highest quality standards.